PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307805

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307805

Global Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

PUBLISHED: June 1, 2023

PAGES: 319 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The global Pemphigus Vulgaris market is expected to reach USD 677.32 million by 2030 from USD 362.59 million in 2022, growing at a CAGR of 8.2% during the forecast period of 2023 to 2030.

Market Segmentation:

Global Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of Global Pemphigus Vulgaris Market Dynamics :

Driver
Rise in patients with rare diseases such as pemphigus vulgaris
Restraint
High cost of treatment
Opportunity
Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the market are:

F-Hoffmann La Roche Ltd.
Sanofi
Regeneron Pharmaceuticals Inc.
Fresenius Kabi AG
Boehringer Ingelheim International GmbH
Johnson & Johnson Services, Inc.
RAKSHIT DRUGS PVT. LTD
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Celltrion Healthcare Co., Ltd.
AbbVie Inc.
Novartis AG
Amgen Inc.
Merck & Co., Inc.
AstraZeneca
Teva Pharmaceutical Industries Ltd
Lilly
Zydus Group
GSK plc.

1 INTRODUCTION 32

1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW 32
1.4 CURRENCY AND PRICING 34
1.5 LIMITATIONS 34
1.6 MARKETS COVERED 34

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.6 MULTIVARIATE MODELLING 44
2.7 MARKET APPLICATION COVERAGE GRID 45
2.8 PRODUCT LIFELINE CURVE 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 SECONDARY SOURCES 49
2.12 ASSUMPTIONS 49

3 EXECUTIVE SUMMARY 50

4 PREMIUM INSIGHTS 52

4.1 PESTEL ANALYSIS 55
4.2 PORTER FIVE FORCES 56
4.3 PATENT ANALYSIS 57
4.4 PATIENT FLOW DIAGRAM 58
4.5 KEY PRICING STRATEGIES 59
4.6 FUTURE THERAPIES 60
4.7 KEY PATIENT ENROLLMENT STRATEGIES 61

5 PIPELINE ANALYSIS 62

6 EPIDEMIOLOGY 63

7 INDUSTRY INSIGHTS 64

8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS 65

9 MARKET OVERVIEW 68

9.1 DRIVERS 70
- 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 70
- 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 70
- 9.1.3 AWARENESS REGARDING THE DISEASE 71
9.2 RESTRAINTS 71
- 9.2.1 STRICT REGULATORY GUIDELINES 71
- 9.2.2 HIGH TREATMENT COSTS 71
9.3 OPPORTUNITIES 72
- 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 72
- 9.3.2 INCREASING HEALTHCARE FACILITIES 72
- 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 73
9.4 CHALLENGES 73
- 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 73
- 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 74

10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 75

10.1 OVERVIEW 76
10.2 TREATMENT 79
- 10.2.1 MEDICATIONS, BY TYPE 79
  - 10.2.1.1 CORTICOSTEROIDS 80
  - 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 80
    - 10.2.1.2.1 AZATHIOPRINE 81
    - 10.2.1.2.2 MYCOPHENALATE MOFETIL 81
    - 10.2.1.2.3 METHOTREXATE 81
    - 10.2.1.2.4 CYCLOPHOSPHAMIDE 81
    - 10.2.1.2.5 MIZORIBINE 81
    - 10.2.1.2.6 OTHERS 81
  - 10.2.1.3 ANTI- INFLAMMATORY AGENTS 81
    - 10.2.1.3.1 DIAMINODYPHENYL SULFONE 82
    - 10.2.1.3.2 TETRACYCLINE 82
    - 10.2.1.3.3 OTHERS 82
  - 10.2.1.4 BIOLOGICS 82
  - 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 82
  - 10.2.1.6 ANTIBIOTICS 82
  - 10.2.1.7 ANTIFUNGALS 82
  - 10.2.1.8 ANTIVIRALS 82
  - 10.2.1.9 OTHER MEDICATIONS 82
- 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 82
  - 10.2.2.1 ORAL 83
  - 10.2.2.2 TOPICAL 83
  - 10.2.2.3 PARENTERAL 83
  - 10.2.2.4 OTHERS 83
- 10.2.3 MEDICATIONS, BY DRUG TYPE 83
  - 10.2.3.1 GENERIC 84
  - 10.2.3.2 BRANDED 84
10.3 DIAGNOSIS 84
- 10.3.1 SKIN BIOPSY 85
- 10.3.2 BLOOD TEST 85
- 10.3.3 ENDOSCOPY 85

11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 86

11.1 OVERVIEW 87
11.2 ADULTS 90
11.3 GERIATRIC 91
11.4 PEDIATRIC 92

12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER 93

12.1 OVERVIEW 94
12.2 HOSPITALS 97
12.3 SPECIALTY CLINICS 97
12.4 RESEARCH INSTITUTES 98
12.5 OTHERS 99

13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 100

13.1 OVERVIEW 101
13.2 HOSPITALS PHARMACY 104
13.3 RETAIL PHARMACY 104
13.4 ONLINE PHARMACY 105

14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 106

14.1 OVERVIEW 107
14.2 NORTH AMERICA 112
- 14.2.1 U.S. 120
- 14.2.2 CANADA 124
- 14.2.3 MEXICO 128
14.3 EUROPE 132
- 14.3.1 GERMANY 141
- 14.3.2 U.K. 145
- 14.3.3 FRANCE 149
- 14.3.4 ITALY 153
- 14.3.5 SPAIN 157
- 14.3.6 SWITZERLAND 161
- 14.3.7 TURKEY 165
- 14.3.8 RUSSIA 169
- 14.3.9 BELGIUM 173
- 14.3.10 NETHERLANDS 177
- 14.3.11 REST OF EUROPE 180
14.4 ASIA-PACIFIC 181
- 14.4.1 CHINA 190
- 14.4.2 INDIA 194
- 14.4.3 SOUTH KOREA 198
- 14.4.4 MALAYSIA 202
- 14.4.5 JAPAN 206
- 14.4.6 AUSTRALIA 210
- 14.4.7 SINGAPORE 214
- 14.4.8 THAILAND 218
- 14.4.9 INDONESIA 222
- 14.4.10 PHILIPPINES 226
- 14.4.11 REST OF ASIA-PACIFIC 229
14.5 SOUTH AMERICA 230
- 14.5.1 BRAZIL 238
- 14.5.2 ARGENTINA 242
- 14.5.3 REST OF SOUTH AMERICA 246
14.6 MIDDLE EAST AND AFRICA 247
- 14.6.1 SAUDI ARABIA 255
- 14.6.2 EGYPT 259
- 14.6.3 U.A.E. 263
- 14.6.4 SOUTH AFRICA 267
- 14.6.5 ISRAEL 271
- 14.6.6 REST OF MIDDLE EAST AND AFRICA 274

15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 275

15.1 COMPANY SHARE ANALYSIS: GLOBAL 275
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 276
15.3 COMPANY SHARE ANALYSIS: EUROPE 277
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 278

16 SWOT ANALYSIS 279

17 COMPANY PROFILE 280

17.1 ABBVIE INC. 280
- 17.1.1 COMPANY SNAPSHOT 280
- 17.1.2 REVENUE ANALYSIS 280
- 17.1.3 COMPANY SHARE ANALYSIS 281
- 17.1.4 PRODUCT PORTFOLIO 281
- 17.1.5 RECENT DEVELOPMENTS 282
17.2 MERCK & CO., INC., 283
- 17.2.1 COMPANY SNAPSHOT 283
- 17.2.2 REVENUE ANALYSIS 283
- 17.2.3 COMPANY SHARE ANALYSIS 284
- 17.2.4 PRODUCT PORTFOLIO 284
- 17.2.5 RECENT DEVELOPMENT 284
17.3 SANOFI 285
- 17.3.1 COMPANY SNAPSHOT 285
- 17.3.2 REVENUE ANALYSIS 285
- 17.3.3 COMPANY SHARE ANALYSIS 286
- 17.3.4 PRODUCT PORTFOLIO 286
- 17.3.5 RECENT DEVELOPMENT 286
17.4 REGENERON PHARMACEUTICALS INC. 287
- 17.4.1 COMPANY SNAPSHOT 287
- 17.4.2 REVENUE ANALYSIS 287
- 17.4.3 COMPANY SHARE ANALYSIS 288
- 17.4.4 PRODUCT PORTFOLIO 288
- 17.4.5 RECENT DEVELOPMENT 288
17.5 NOVARTIS AG 289
- 17.5.1 COMPANY SNAPSHOT 289
- 17.5.2 REVENUE ANALYSIS 289
- 17.5.3 COMPANY SHARE ANALYSIS 290
- 17.5.4 PRODUCT PORTFOLIO 290
- 17.5.5 RECENT DEVELOPMENT 290
17.6 AMGEN INC. 291
- 17.6.1 COMPANY SNAPSHOT 291
- 17.6.2 REVENUE ANALYSIS 291
- 17.6.3 PRODUCT PORTFOLIO 292
- 17.6.4 RECENT DEVELOPMENTS 292
17.7 ASTRAZENECA 293
- 17.7.1 COMPANY SNAPSHOT 293
- 17.7.2 REVENUE ANALYSIS 293
- 17.7.3 COMPANY SHARE ANALYSIS 294
- 17.7.4 PRODUCT PORTFOLIO 294
- 17.7.5 RECENT DEVELOPMENTS 295
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 296
- 17.8.1 COMPANY SNAPSHOT 296
- 17.8.2 REVENUE ANALYSIS 296
- 17.8.3 PRODUCT PORTFOLIO 297
- 17.8.4 RECENT DEVELOPMENT 297
17.9 CELLTRION HEALTHCARE CO., LTD 298
- 17.9.1 COMPANY SNAPSHOT 298
- 17.9.2 REVENUE ANALYSIS 298
- 17.9.3 PRODUCT PORTFOLIO 299
- 17.9.4 RECENT DEVELOPMENTS 299
17.10 F. HOFFMANN- LA ROCHE LTD. 300
- 17.10.1 COMPANY SNAPSHOT 300
- 17.10.2 REVENUE ANALYSIS 300
- 17.10.3 PRODUCT PORTFOLIO 301
- 17.10.4 RECENT DEVELOPMENT 301
17.11 FRESENIUS KABI AG 302
- 17.11.1 COMPANY SNAPSHOT 302
- 17.11.2 REVENUE ANALYSIS 302
- 17.11.3 PRODUCT PORTFOLIO 303
- 17.11.4 RECENT DEVELOPMENT 303
17.12 GSK PLC 304
- 17.12.1 COMPANY SNAPSHOT 304
- 17.12.2 REVENUE ANALYSIS 304
- 17.12.3 PRODUCT PORTFOLIO 305
- 17.12.4 RECENT DEVELOPMENT 305
17.13 JOHNSON & JOHNSON SERVICES, INC. 306
- 17.13.1 COMPANY SNAPSHOT 306
- 17.13.2 REVENUE ANALYSIS 306
- 17.13.3 COMPANY SHARE ANALYSIS 307
- 17.13.4 PRODUCT PORTFOLIO 307
- 17.13.5 RECENT DEVELOPMENT 307
17.14 LILLY 308
- 17.14.1 COMPANY SNAPSHOT 308
- 17.14.2 REVENUE ANALYSIS 308
- 17.14.3 PRODUCT PORTFOLIO 309
- 17.14.4 RECENT DEVELOPMENT 309
17.15 PFIZER INC. 310
- 17.15.1 COMPANY SNAPSHOT 310
- 17.15.2 REVENUE ANALYSIS 310
- 17.15.3 PRODUCT PORTFOLIO 311
- 17.15.4 RECENT DEVELOPMENT 311
17.16 RAKSHIT DRUGS PVT. LTD 312
- 17.16.1 COMPANY SNAPSHOT 312
- 17.16.2 PRODUCT PORTFOLIO 312
- 17.16.3 RECENT DEVELOPMENT 312
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 313
- 17.17.1 COMPANY SNAPSHOT 313
- 17.17.2 REVENUE ANALYSIS 313
- 17.17.3 PRODUCT PORTFOLIO 314
- 17.17.4 RECENT DEVELOPMENT 314
17.18 ZYDUS GROUP 315
- 17.18.1 COMPANY SNAPSHOT 315
- 17.18.2 REVENUE ANALYSIS 315
- 17.18.3 PRODUCT PORTFOLIO 316
- 17.18.4 RECENT DEVELOPMENT 316

18 QUESTIONNAIRE 317

19 RELATED REPORTS 319

LIST OF TABLES

TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 57
TABLE 2 GLOBAL PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 62
TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 78
TABLE 4 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 5 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
TABLE 6 GLOBAL STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
TABLE 7 GLOBAL ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 81
TABLE 8 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 83
TABLE 9 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 83
TABLE 10 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 11 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 85
TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 89
TABLE 13 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 14 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 15 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 96
TABLE 17 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 18 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 19 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 20 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 21 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 103
TABLE 22 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 23 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 24 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 25 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 116
TABLE 27 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 116
TABLE 28 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
TABLE 29 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 31 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 117
TABLE 32 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
TABLE 33 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 118
TABLE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 119
TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
TABLE 37 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 120
TABLE 38 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
TABLE 39 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
TABLE 40 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
TABLE 41 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 121
TABLE 42 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 122
TABLE 43 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 44 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 122
TABLE 45 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 123
TABLE 47 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 124
TABLE 48 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 49 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
TABLE 50 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
TABLE 51 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 125
TABLE 52 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 126
TABLE 53 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
TABLE 54 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 126
TABLE 55 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 127
TABLE 57 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 128
TABLE 58 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 59 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 60 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 61 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 129
TABLE 62 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 130
TABLE 63 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 64 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 130
TABLE 65 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
TABLE 67 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 136
TABLE 68 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 136
TABLE 69 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 70 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 71 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
TABLE 72 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 138
TABLE 73 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 138
TABLE 74 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 139
TABLE 75 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 139
TABLE 76 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 140
TABLE 78 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 141
TABLE 79 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
TABLE 80 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 81 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 82 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 142
TABLE 83 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 143
TABLE 84 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
TABLE 85 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 143
TABLE 86 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
TABLE 88 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 145
TABLE 89 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 90 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
TABLE 91 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 146
TABLE 92 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 146
TABLE 93 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 147
TABLE 94 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
TABLE 95 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 147
TABLE 96 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
TABLE 98 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 149
TABLE 99 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
TABLE 100 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 101 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 102 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 150
TABLE 103 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 151
TABLE 104 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
TABLE 105 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 151
TABLE 106 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 151
TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
TABLE 108 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 153
TABLE 109 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
TABLE 110 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
TABLE 111 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
TABLE 112 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 154
TABLE 113 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 155
TABLE 114 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 155
TABLE 115 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 155
TABLE 116 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 155
TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 156
TABLE 118 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 157
TABLE 119 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 120 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
TABLE 121 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
TABLE 122 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 158
TABLE 123 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 159
TABLE 124 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 125 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 159
TABLE 126 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 159
TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
TABLE 128 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 161
TABLE 129 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 161
TABLE 130 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 131 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 132 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 162
TABLE 133 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 162
TABLE 134 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
TABLE 135 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 163
TABLE 136 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 163
TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 164
TABLE 138 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 165
TABLE 139 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
TABLE 140 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
TABLE 141 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
TABLE 142 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 166
TABLE 143 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 167
TABLE 144 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 167
TABLE 145 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 167
TABLE 146 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 167
TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
TABLE 148 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 169
TABLE 149 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
TABLE 150 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
TABLE 151 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
TABLE 152 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 170
TABLE 153 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 171
TABLE 154 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
TABLE 155 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 171
TABLE 156 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 171
TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 172
TABLE 158 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 173
TABLE 159 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 173
TABLE 160 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
TABLE 161 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
TABLE 162 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 174
TABLE 163 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 175
TABLE 164 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
TABLE 165 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 175
TABLE 166 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 175
TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
TABLE 168 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 177
TABLE 169 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
TABLE 170 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
TABLE 171 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
TABLE 172 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 178
TABLE 173 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 178
TABLE 174 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
TABLE 175 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 179
TABLE 176 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 179
TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 179
TABLE 178 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 180
TABLE 179 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 185
TABLE 180 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 185
TABLE 181 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
TABLE 182 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
TABLE 183 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
TABLE 184 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 187
TABLE 185 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 187
TABLE 186 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
TABLE 187 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 188
TABLE 188 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 188
TABLE 189 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 189
TABLE 190 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 190
TABLE 191 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
TABLE 192 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
TABLE 193 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
TABLE 194 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 191
TABLE 195 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 192
TABLE 196 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
TABLE 197 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 192
TABLE 198 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 192
TABLE 199 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 193
TABLE 200 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 194
TABLE 201 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 202 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
TABLE 203 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
TABLE 204 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 195
TABLE 205 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 196
TABLE 206 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
TABLE 207 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 196

TABLE 208 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 196
TABLE 209 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 197
TABLE 210 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 198
TABLE 211 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 198
TABLE 212 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 213 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 214 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 199
TABLE 215 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 200
TABLE 216 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
TABLE 217 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 200
TABLE 218 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 201
TABLE 219 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 201
TABLE 220 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 202
TABLE 221 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 202
TABLE 222 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 203
TABLE 223 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 203
TABLE 224 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 203
TABLE 225 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 204
TABLE 226 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 204
TABLE 227 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 204
TABLE 228 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 205
TABLE 229 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 205
TABLE 230 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 206
TABLE 231 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
TABLE 232 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
TABLE 233 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 207
TABLE 234 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 207
TABLE 235 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 207
TABLE 236 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 208
TABLE 237 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 208
TABLE 238 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 208
TABLE 239 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 209
TABLE 240 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 210
TABLE 241 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 210
TABLE 242 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
TABLE 243 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 211
TABLE 244 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 211
TABLE 245 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 212
TABLE 246 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 212
TABLE 247 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 212
TABLE 248 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 213
TABLE 249 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 213
TABLE 250 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 214
TABLE 251 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 214
TABLE 252 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 215
TABLE 253 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 215
TABLE 254 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 215
TABLE 255 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 216
TABLE 256 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 216
TABLE 257 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 216
TABLE 258 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 217
TABLE 259 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 217
TABLE 260 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 218
TABLE 261 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 218
TABLE 262 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 219
TABLE 263 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 219
TABLE 264 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 219
TABLE 265 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 220
TABLE 266 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 220
TABLE 267 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 220
TABLE 268 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 221
TABLE 269 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 221
TABLE 270 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 222
TABLE 271 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 222
TABLE 272 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 222
TABLE 273 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 223
TABLE 274 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 223
TABLE 275 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 223
TABLE 276 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 224
TABLE 277 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 224
TABLE 278 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 224
TABLE 279 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 225
TABLE 280 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 226
TABLE 281 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 226
TABLE 282 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 226
TABLE 283 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 227
TABLE 284 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 227
TABLE 285 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 227
TABLE 286 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 227
TABLE 287 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 228
TABLE 288 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 228
TABLE 289 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 228
TABLE 290 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 229
TABLE 291 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 234
TABLE 292 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 234
TABLE 293 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 234
TABLE 294 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 235
TABLE 295 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 235
TABLE 296 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 235
TABLE 297 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 236
TABLE 298 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 236
TABLE 299 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 236
TABLE 300 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 237
TABLE 301 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 238
TABLE 302 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 238
TABLE 303 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 239
TABLE 304 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 239
TABLE 305 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 239
TABLE 306 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 240
TABLE 307 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 240
TABLE 308 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 240
TABLE 309 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 240
TABLE 310 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 241
TABLE 311 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 242
TABLE 312 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 242
TABLE 313 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 243
TABLE 314 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 243
TABLE 315 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 243
TABLE 316 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 244
TABLE 317 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 244
TABLE 318 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 244
TABLE 319 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 245
TABLE 320 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 245
TABLE 321 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 246
TABLE 322 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 251
TABLE 323 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 251
TABLE 324 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 251
TABLE 325 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 252
TABLE 326 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 252
TABLE 327 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 252
TABLE 328 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 253
TABLE 329 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 253
TABLE 330 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 253
TABLE 331 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 254
TABLE 332 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 254
TABLE 333 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 255
TABLE 334 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 255
TABLE 335 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 256
TABLE 336 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 256
TABLE 337 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 256
TABLE 338 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 257
TABLE 339 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 257
TABLE 340 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 257
TABLE 341 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 258
TABLE 342 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 258
TABLE 343 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 259
TABLE 344 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 259
TABLE 345 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 260
TABLE 346 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 260
TABLE 347 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 260
TABLE 348 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 261
TABLE 349 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 261
TABLE 350 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 261
TABLE 351 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 261
TABLE 352 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 262
TABLE 353 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 263
TABLE 354 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 263
TABLE 355 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 264
TABLE 356 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 264
TABLE 357 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 264
TABLE 358 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 265
TABLE 359 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 265
TABLE 360 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 265
TABLE 361 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 265
TABLE 362 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 266
TABLE 363 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 267
TABLE 364 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 267
TABLE 365 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 268
TABLE 366 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 268
TABLE 367 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 268
TABLE 368 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 269
TABLE 369 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 269
TABLE 370 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 269
TABLE 371 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 270
TABLE 372 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 270

LIST OF FIGURES

FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 40
FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 41
FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 42
FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 42
FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 43
FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 45
FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 47
FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 48
FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION 51
FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 52
FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 52
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 53
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 54
FIGURE 15 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 58
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PEMPHIGUS VULGARIS MARKET 69
FIGURE 17 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 76
FIGURE 18 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 77
FIGURE 19 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 77
FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 78
FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 87
FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 88
FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 88
FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 89
FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 94
FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 95
FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 95
FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 101
FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 102
FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 102
FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 103
FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 108
FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022) 109
FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2023 & 2030) 109
FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022 & 2030) 110
FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023 & 2030) 110
FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 113
FIGURE 39 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 114
FIGURE 40 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 114
FIGURE 41 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 115
FIGURE 42 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023-2030) 115
FIGURE 43 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 133
FIGURE 44 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 134
FIGURE 45 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 134
FIGURE 46 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 135
FIGURE 47 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 135
FIGURE 48 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 182
FIGURE 49 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 183
FIGURE 50 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 183
FIGURE 51 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 184
FIGURE 52 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 184
FIGURE 53 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 231
FIGURE 54 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 232
FIGURE 55 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 232
FIGURE 56 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 233
FIGURE 57 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 233
FIGURE 58 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 248
FIGURE 59 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 249
FIGURE 60 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 249
FIGURE 61 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 250
FIGURE 62 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 250
FIGURE 63 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 275
FIGURE 64 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 276
FIGURE 65 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 277
FIGURE 66 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 278

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ